The HDAC6 Inhibitor Tubacin Induces Release of CD133+ Extracellular Vesicles From Cancer Cells

Tumor‐derived extracellular vesicles (EVs) are emerging as an important mode of intercellular communication, capable of transferring biologically active molecules that facilitate the malignant growth and metastatic process. CD133 (Prominin‐1), a stem cell marker implicated in tumor initiation, differentiation and resistance to anti‐cancer therapy, is reportedly associated with EVs in various types of cancer. However, little is known about the factors that regulate the release of these CD133+ EVs. Here, we report that the HDAC6 inhibitor tubacin promoted the extracellular release of CD133+ EVs from human FEMX‐I metastatic melanoma and Caco‐2 colorectal carcinoma cells, with a concomitant downregulation of intracellular CD133. This effect was specific for tubacin, as inhibition of HDAC6 deacetylase activity by another selective HDAC6 inhibitor, ACY‐1215 or the pan‐HDAC inhibitor trichostatin A (TSA), and knockdown of HDAC6 did not enhance the release of CD133+ EVs. The tubacin‐induced EV release was associated with changes in cellular lipid composition, loss of clonogenic capacity and decrease in the ability to form multicellular aggregates. These findings indicate a novel potential anti‐tumor mechanism for tubacin in CD133‐expressing malignancies. J. Cell. Biochem. 118: 4414–4424, 2017. © 2017 Wiley Periodicals, Inc.

[1]  S. Barsky,et al.  Nuclear transport of cancer extracellular vesicle-derived biomaterials through nuclear envelope invagination-associated late endosomes , 2017, Oncotarget.

[2]  G. Camussi,et al.  Extracellular vesicle-mediated modulation of angiogenesis. , 2016, Histology and histopathology.

[3]  J. Meldolesi,et al.  Ectosomes and exosomes: shedding the confusion between extracellular vesicles. , 2015, Trends in cell biology.

[4]  Michael A. Hollingsworth,et al.  Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver , 2015, Nature Cell Biology.

[5]  Alissa M. Weaver,et al.  Directional cell movement through tissues is controlled by exosome secretion , 2015, Nature Communications.

[6]  R. Barrera-Rodríguez,et al.  Multidrug resistance characterization in multicellular tumour spheroids from two human lung cancer cell lines , 2015, Cancer Cell International.

[7]  Siyuan Zhang,et al.  The Role of Multicellular Aggregation in the Survival of ErbB2-positive Breast Cancer Cells during Extracellular Matrix Detachment* , 2015, The Journal of Biological Chemistry.

[8]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[9]  O. Goodman,et al.  Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP , 2014, Molecular Cancer Research.

[10]  B. Wattenberg,et al.  The histone deacetylase-6 inhibitor tubacin directly inhibits de novo sphingolipid biosynthesis as an off-target effect. , 2014, Biochemical and biophysical research communications.

[11]  N. Vitale,et al.  Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2 , 2014, Nature Communications.

[12]  Alissa M. Weaver,et al.  Exosome secretion is enhanced by invadopodia and drives invasive behavior. , 2013, Cell reports.

[13]  Kim Ekroos,et al.  Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. , 2013, Biochimica et biophysica acta.

[14]  Zhong Li,et al.  CD133: a stem cell biomarker and beyond , 2013, Experimental Hematology & Oncology.

[15]  R. M. Pope,et al.  Biochemical and biological characterization of exosomes containing prominin-1/CD133 , 2013, Molecular Cancer.

[16]  D. Corbeil,et al.  Wnt interaction and extracellular release of prominin-1/CD133 in human malignant melanoma cells. , 2013, Experimental cell research.

[17]  L. O’Driscoll,et al.  Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes , 2012, PloS one.

[18]  A. Gingras,et al.  Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. , 2012, Cell reports.

[19]  A. Cashikar,et al.  Multivesicular body morphogenesis. , 2012, Annual review of cell and developmental biology.

[20]  Stanley N Cohen,et al.  Formation and release of arrestin domain-containing protein 1-mediated microvesicles (ARMMs) at plasma membrane by recruitment of TSG101 protein , 2012, Proceedings of the National Academy of Sciences.

[21]  M. Campiglio,et al.  Potential role of HER2‐overexpressing exosomes in countering trastuzumab‐based therapy , 2012, Journal of cellular physiology.

[22]  Peter Kuhn,et al.  Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors , 2012, Physical biology.

[23]  Suresh Mathivanan,et al.  ExoCarta 2012: database of exosomal proteins, RNA and lipids , 2011, Nucleic Acids Res..

[24]  W. Huttner,et al.  Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles—a role of the endocytic–exocytic pathway , 2011, EMBO molecular medicine.

[25]  T. Yao,et al.  The Microtubule-associated Histone Deacetylase 6 (HDAC6) Regulates Epidermal Growth Factor Receptor (EGFR) Endocytic Trafficking and Degradation* , 2010, The Journal of Biological Chemistry.

[26]  S. Kaushal,et al.  Exosomes as a tumor immune escape mechanism: possible therapeutic implications , 2008, Journal of Translational Medicine.

[27]  M. Wicha,et al.  Cancer stem cells: a step toward the cure. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Schwille,et al.  Ceramide Triggers Budding of Exosome Vesicles into Multivesicular Endosomes , 2008, Science.

[29]  A. Llorente,et al.  Cholesterol regulates prostasome release from secretory lysosomes in PC-3 human prostate cancer cells. , 2007, European journal of cell biology.

[30]  O. Fodstad,et al.  Global comparative gene expression analysis of melanoma patient samples, derived cell lines and corresponding tumor xenografts. , 2007, Cancer genomics & proteomics.

[31]  Fabrice P Cordelières,et al.  Histone Deacetylase 6 Inhibition Compensates for the Transport Deficit in Huntington's Disease by Increasing Tubulin Acetylation , 2007, The Journal of Neuroscience.

[32]  I. Mérida,et al.  A new role of diacylglycerol kinase alpha on the secretion of lethal exosomes bearing Fas ligand during activation-induced cell death of T lymphocytes. , 2007, Biochimie.

[33]  W. Huttner,et al.  Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells , 2005, Journal of Cell Science.

[34]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[35]  M. Record,et al.  PLD2 is enriched on exosomes and its activity is correlated to the release of exosomes , 2004, FEBS letters.

[36]  Stefan Matile,et al.  Role of LBPA and Alix in Multivesicular Liposome Formation and Endosome Organization , 2004, Science.

[37]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[39]  B. Molnár,et al.  Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  W. Huttner,et al.  Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane , 2000, Nature Cell Biology.

[41]  Minoru Yoshida,et al.  Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm , 2000, Current Biology.

[42]  S. Schreiber,et al.  The identification of myriocin-binding proteins. , 1999, Chemistry & biology.

[43]  Y. Miyake,et al.  Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. , 1995, Biochemical and biophysical research communications.

[44]  P. Olive,et al.  Drug and radiation resistance in spheroids: cell contact and kinetics , 1994, Cancer and Metastasis Reviews.

[45]  M. Boyd,et al.  Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. , 1988, Cancer research.

[46]  G. Nicolson,et al.  Malignant melanoma cell lines selected in vitro for increased homotypic adhesion properties have increased experimental metastatic potential , 1986, Clinical & Experimental Metastasis.

[47]  R. Ting,et al.  Formation of larger cell aggregates by transformed cells: an in vitro index of cell transformation. , 1976, Journal of the National Cancer Institute.

[48]  L. Liotta,et al.  The significance of hematogenous tumor cell clumps in the metastatic process. , 1976, Cancer research.

[49]  J. Huo,et al.  Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells. , 2019, Annals of translational medicine.

[50]  M. Record,et al.  Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. , 2014, Biochimica et biophysica acta.

[51]  J. Bradner,et al.  INHIBITION OF HISTONE DEACETYLASE 6 ACETYLATES AND DISRUPTS THE CHAPERONE FUNCTION OF HEAT SHOCK PROTEIN 90: A NOVEL BASIS OF ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS , 2005 .